Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLO1 | Q04760 | 2/20 | 0.39 |
| ▸ | CDK4 | P11802 | 4/20 | 0.38 |
| ▸ | CCND1 | P24385 | 4/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | HTR2C | P28335 | 2/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5778093 | 0.91 | GLO1 (0.41) | GLO1CDK4CCND1HTR2AHTR2C | |
| SCHEMBL13726782 | 0.87 | CDK4 (0.38) | GLO1CDK4CCND1HTR2AHTR2C | |
| SCHEMBL6231638 | 0.83 | HTR2C (0.33) | CDK4CCND1HTR2AHTR2C | |
| SCHEMBL694594 | 0.81 | CDK4 (0.41) | CDK4CCND1HTR2AHTR2CMAPK1 | |
| SCHEMBL5777899 | 0.81 | MAPK1 (0.39) | CDK4CCND1MEN1KMT2ANPC1 | |
| SCHEMBL5814894 | 0.79 | CDK4 (0.44) | CDK4CCND1HTR2AHTR2CGRIN2B | |
| SCHEMBL5778193 | 0.78 | CDK4 (0.41) | GLO1CDK4CCND1HTR2AHTR2C | |
| SCHEMBL1450476 | 0.78 | CDK4 (0.41) | CDK4CCND1HTR2AHTR2CMEN1 | |
| SCHEMBL27382849 | 0.78 | CDK4 (0.41) | CDK4CCND1HTR2AHTR2CMAPK1 | |
| SCHEMBL5780811 | 0.78 | LMNA (0.41) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240116910-A1 | Heterocycles as WIP1 Inhibitors | PMV PHARMACEUTICALS, INC. | 2024-04-11 | — | — | US | claimed |
| US-20240116910-A1 | Heterocycles as WIP1 Inhibitors | PMV PHARMACEUTICALS, INC. | 2024-04-11 | — | — | US | disclosed |
| US-7667036-B2 | MAPKAP-K2 (mitogen-activated protein kinase-activated protein kinase 2) inhibitors; inflammatory, autoimmune disease, destructive bone disorder, cancer and/or tumor growth; angiogenesis, diabetes and neurological disorders | TEIJIN PHARMA LIMITED (JP) | 2010-02-23 | — | — | US | disclosed |
| EP-1780212-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVE | Teijin Pharma Limited (JP) | 2007-05-02 | — | — | EP | disclosed |
| US-20060135514-A1 | Pyrazolo[1,5-a]pyrimidine derivatives | TEIJIN PHARMA LIMITED | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116910-A1 | Heterocycles as WIP1 Inhibitors | WAPL, WHR1, G3BP1 | GLO1 2910/4885CDK4 262/4885CCND1 675/4885 |
| US-20060135514-A1 | Pyrazolo[1,5-a]pyrimidine derivatives | MAPKAPK2, MAPKAPK5, MAP4K2 | GLO1 4564/4885CDK4 538/4885CCND1 768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.